Loading viewer...
investor_presentation
Format: PDF investor_presentation
21 November 2019INTERIM RESULTS PRESENTATION
21 November 2019INTERIM RESULTS
PRESENTATIONProviso
Please note that matters discussed in today's presentation may contain forward looking statements which are
subject to various risks and uncertainties and other factors including, but not limited to:
changes in the political and/or economic environment that would materially affect the Investec group
changes in legislation or regulation impacting the Investec group’s operations or its accounting policies
changes in business conditions that will have a significant impact on the Investec group’s operations
changes in exchange rates and/or tax rates from the prevailing rates at 30 September 2019
changes in the structure of the markets, client demand or the competitive environment
A number of these factors are beyond the Investec group’s control
These factors may cause the Investec group’s actual future results, performance or achievements in markets in
which it operates to differ from those expressed or implied
Any forward looking statements made are based on knowledge of the group at 20 November 2019
Unless otherwise stated, all information in this presentation has been prepared on a statutory basis
1.Overview –Fani Titi, Joint Group Chief Executive Officer
2.Financial review –Nishlan Samujh, Group Finance Director
Bank and Wealth –Fani Titi
Asset Management –Hendrik du Toit, Joint Group Chief Executive Officer
4.Sustainability –Hendrik du Toit
5.Demerger –Hendrik du Toit
31.Overview –Fani Titi, Joint Group Chief Executive OfficerOVERVIEW5Ourclient franchise businesses have made solid progress asevidenced
bystrong net inflows and growth inassets under management,
loan book andcustomer deposits .
Thechallenging environment andcontinued investment inourplatforms
aswell asaseries ofstrategic actions have impacted ouroperating
Investec isontrack todemerge intotwoindependent businesses poised
forlong-term growth andvalue creation forallourstakeholders .Six months under review
6Solid performance against challenging market conditionsSolid operational performance against challenging backdrop
Results in line with pre -close trading update
Adjusted operating profit* of £373.6mn (1.7% down; in line in neutral currency)
Preview truncated — download the full document for the complete content.
presentation
Suven Pharmaceuticals 2023 Investor Presentation
investor_presentationinvestor_presentation
35 Pages
Suven Pharmaceuticals Ltd.